Iovance Biotherapeutics (IOVA) Current Assets (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Current Assets for 17 consecutive years, with $466.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets fell 9.0% year-over-year to $466.5 million; the TTM figure through Mar 2026 stood at $466.5 million (down 9.0% YoY), while the FY2025 annual figure was $442.7 million, down 3.14% from the prior year.
• Current Assets climbed to $466.5 million in Q1 2026 per IOVA's latest filing, from $442.7 million in the prior quarter.
• Across five years, Current Assets topped out at $637.8 million in Q1 2023 and bottomed at $274.9 million in Q2 2023.
• Historically, Current Assets has averaged $432.6 million across 5 years, with a median of $431.6 million in 2022.
• On a YoY basis, Current Assets climbed as much as 48.46% in 2024 and fell as far as 39.55% in 2024.
• Iovance Biotherapeutics' Current Assets stood at $479.1 million in 2022, then sank by 35.75% to $307.8 million in 2023, then surged by 48.46% to $457.0 million in 2024, then slipped by 3.14% to $442.7 million in 2025, then advanced by 5.38% to $466.5 million in 2026.
• Business Quant data shows IOVA's Current Assets at $466.5 million in Q1 2026, $442.7 million in Q4 2025, and $429.1 million in Q3 2025.